Takeda Pharmaceutical Company LimitedJP:4502

Market cap

¥6.54T

P/E ratio

36.7x

	Mar 31, 2015	Mar 31, 2016	Mar 31, 2017	Mar 31, 2018	Mar 31, 2019	Mar 31, 2020	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023
Revenue	-	-	-	1,770,531	2,097,224	3,291,188	3,197,812	3,569,006	4,027,478
Cost of sales	-	-	-	495,921	659,690	1,089,764	994,308	1,106,846	1,244,072
Selling, general and administrative expenses	-	-	-	628,106	717,599	964,737	875,663	886,361	997,309
Research and development expenses	-	-	-	325,441	368,298	492,381	455,833	526,087	633,325
Amortization and impairment losses on intangible assets associated with products	-	-	-	122,131	203,372	455,420	421,864	472,915	542,443
Other operating income	-	-	-	169,412	159,863	60,213	318,020	43,123	25,424
Other operating expenses	-	-	-	126,555	103,159	248,691	258,895	159,075	145,247
Operating profit (loss)	-	-	-	241,789	237,685	100,408	509,269	460,844	490,505
Finance income	-	-	-	39,543	16,843	27,831	105,521	23,700	62,913
Finance costs	-	-	-	31,928	83,289	165,006	248,631	166,607	169,698
Share of profit (loss) of investments accounted for using equity method	-	-	-	-32,199	-43,627	-23,987	76	-15,367	-8,630
Profit (loss) before tax	-	-	-	217,205	127,612	-60,754	366,235	302,571	375,090
Income tax expense	-	-	-	30,497	-7,468	-105,044	-9,936	72,405	58,052
Profit (loss)	-	-	-	186,708	135,080	44,290	376,171	230,166	317,038
Owners of parent	-	-	-	186,886	135,192	44,241	376,005	230,059	317,017
Non-controlling interests	-	-	-	-178	-112	49	166	107	21
Total	-	-	-	186,708	135,080	44,290	376,171	230,166	317,038
Basic earnings (loss) per share	-	-	-	239.35	140.61	28.41	240.72	147.14	204.29
Diluted earnings (loss) per share	-	-	-	237.56	139.82	28.25	238.96	145.87	201.94